ATE426043T1 - Verfahren zur identifizierung des brustkrebsrisikos - Google Patents

Verfahren zur identifizierung des brustkrebsrisikos

Info

Publication number
ATE426043T1
ATE426043T1 AT03787201T AT03787201T ATE426043T1 AT E426043 T1 ATE426043 T1 AT E426043T1 AT 03787201 T AT03787201 T AT 03787201T AT 03787201 T AT03787201 T AT 03787201T AT E426043 T1 ATE426043 T1 AT E426043T1
Authority
AT
Austria
Prior art keywords
breast cancer
methods
cancer risk
subject
identifying
Prior art date
Application number
AT03787201T
Other languages
English (en)
Inventor
Richard Roth
Matthew Nelson
Andreas Braun
Stefan Kammerer
Rikard Reneland
Original Assignee
Sequenom Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequenom Inc filed Critical Sequenom Inc
Application granted granted Critical
Publication of ATE426043T1 publication Critical patent/ATE426043T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Peptides Or Proteins (AREA)
AT03787201T 2002-11-25 2003-11-25 Verfahren zur identifizierung des brustkrebsrisikos ATE426043T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42913602P 2002-11-25 2002-11-25
US49023403P 2003-07-24 2003-07-24

Publications (1)

Publication Number Publication Date
ATE426043T1 true ATE426043T1 (de) 2009-04-15

Family

ID=32397178

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03787201T ATE426043T1 (de) 2002-11-25 2003-11-25 Verfahren zur identifizierung des brustkrebsrisikos

Country Status (7)

Country Link
US (5) US7510835B2 (de)
EP (2) EP1565582A4 (de)
AT (1) ATE426043T1 (de)
AU (4) AU2003295986A1 (de)
CA (2) CA2505784A1 (de)
DE (1) DE60326748D1 (de)
WO (4) WO2004047514A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US20050064442A1 (en) * 2002-11-25 2005-03-24 Roth Richard B. Methods for identifying risk of breast cancer and treatments thereof
WO2004047514A2 (en) 2002-11-25 2004-06-10 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
WO2005014846A2 (en) * 2003-07-24 2005-02-17 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
WO2005118856A1 (en) * 2004-05-27 2005-12-15 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
US20070266003A1 (en) * 2006-05-09 2007-11-15 0752004 B.C. Ltd. Method and system for constructing dynamic and interacive family trees based upon an online social network
US20080163824A1 (en) * 2006-09-01 2008-07-10 Innovative Dairy Products Pty Ltd, An Australian Company, Acn 098 382 784 Whole genome based genetic evaluation and selection process
US20080189047A1 (en) * 2006-11-01 2008-08-07 0752004 B.C. Ltd. Method and system for genetic research using genetic sampling via an interactive online network
JP2010527603A (ja) * 2007-05-25 2010-08-19 ディコーデ ジェネテクス イーエイチエフ 乳癌のリスクアセスメント、診断、予後診断および治療における使用のためのマーカーとしてのＣＨＲ５ｐ１２および１０ｑ２６上の遺伝的変異
US20090049856A1 (en) * 2007-08-20 2009-02-26 Honeywell International Inc. Working fluid of a blend of 1,1,1,3,3-pentafluoropane, 1,1,1,2,3,3-hexafluoropropane, and 1,1,1,2-tetrafluoroethane and method and apparatus for using
US20110311539A1 (en) * 2007-09-17 2011-12-22 Ludwig Institute For Cancer Research Ltd Diagnosis and treatment of cancer using cancer-testis antigens
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
GB2541463A (en) * 2015-08-21 2017-02-22 Univ Of Ha'il Novel methods
EP3478164B1 (de) * 2016-06-29 2024-01-10 Niramai Health Analytix Pvt. Ltd. Klassifizierung des hormonrezeptorstatus von bösartigem tumorgewebe aus thermografischen bildern der brust
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20200147120A1 (en) * 2017-04-05 2020-05-14 National University Corporation Chiba University Function inhibitor of swi/snf complexes
CN111190393B (zh) * 2018-11-14 2021-07-23 长鑫存储技术有限公司 半导体制程自动化控制方法及装置
US10851376B2 (en) * 2018-12-28 2020-12-01 The Florida International University Board Of Trustees Long noncoding RNAs in pulmonary airway inflammation
CN111383737A (zh) * 2018-12-28 2020-07-07 康多富国际有限公司 癌症保健食品组合确定方法及非瞬时计算机可读存储介质
CN111383736A (zh) * 2018-12-28 2020-07-07 康多富国际有限公司 免疫系统疾病保健食品组合确定方法及其可读取储存媒体
EP4646208A1 (de) 2023-01-06 2025-11-12 Ideaya Biosciences, Inc. Behandlung von er+-brustkrebs mit mangel an homologer rekombination unter verwendung eines parg-hemmers

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466688B1 (de) 1988-07-08 1997-08-06 Chiron Corporation Gap-gen-sequenzen und diagnoseverwendungen davon
US5359078A (en) * 1989-05-19 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Signal transduction inhibitor compounds
US6013431A (en) * 1990-02-16 2000-01-11 Molecular Tool, Inc. Method for determining specific nucleotide variations by primer extension in the presence of mixture of labeled nucleotides and terminators
DE69332715T2 (de) * 1992-11-12 2003-10-16 Merck Sharp & Dohme Ltd., Hoddesdon Transfektierte zelllinie, exprimierend dns die für die nmda-r2a rezeptor untereinheit und für isoformen der nmda-r1 untereinheit des menschlichen nmda-rezeptors kodieren
DE69433811T2 (de) * 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
US6194144B1 (en) * 1993-01-07 2001-02-27 Sequenom, Inc. DNA sequencing by mass spectrometry
US5605798A (en) * 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
EP0765401B1 (de) * 1993-11-17 2001-02-21 Amersham Pharmacia Biotech UK Limited Verfahren zur massenspektroskopischen sequenzanalyse einer nukleinsäure mittels primerverlängerung
US5869242A (en) * 1995-09-18 1999-02-09 Myriad Genetics, Inc. Mass spectrometry to assess DNA sequence polymorphisms
US5928906A (en) * 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US6432668B1 (en) 1997-12-30 2002-08-13 Chiron Corporation Polynucleotides encoding human cyclin-dependent kinase (hPFTAIRE)
EP1254260B1 (de) * 2000-01-12 2006-08-30 The General Hospital Corporation Methoden zur diagnose und behandlung von herzkrankheiten
AU2001288999A1 (en) * 2000-09-08 2002-03-22 Millennium Pharmaceuticals, Inc. 38646, a guanine nucleotide exchange factor and uses therefor
US20020155440A1 (en) * 2000-12-19 2002-10-24 Ljubimova Julia Y. Using overexpression of laminin alpha 4 subunit as a diagnostic and prognostic indicator of malignant tumors
WO2002053018A2 (en) 2001-01-08 2002-07-11 Genomics Collaborative, Inc. Method of detecting polymorphisms associated with breast carcinoma in mhc genes
WO2004047514A2 (en) 2002-11-25 2004-06-10 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
US20050064442A1 (en) * 2002-11-25 2005-03-24 Roth Richard B. Methods for identifying risk of breast cancer and treatments thereof
WO2005014846A2 (en) * 2003-07-24 2005-02-17 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
JP2008520242A (ja) 2004-11-18 2008-06-19 イェール ユニバーシティ 視覚障害を処置するための方法および組成物
US8088587B2 (en) 2005-03-04 2012-01-03 Vanderbilt University Genetic variants increase the risk of age-related macular degeneration
US20070037183A1 (en) 2005-03-07 2007-02-15 Trustees Of Boston University Diagnostic and therapeutic target for macular degeneration

Also Published As

Publication number Publication date
AU2003293141A1 (en) 2004-06-18
DE60326748D1 (de) 2009-04-30
CA2505786A1 (en) 2004-06-10
WO2004047767A2 (en) 2004-06-10
US20060204967A1 (en) 2006-09-14
AU2003295986A1 (en) 2004-06-18
WO2004047514A2 (en) 2004-06-10
EP1565582A2 (de) 2005-08-24
WO2004055196A3 (en) 2005-02-24
AU2003293141A8 (en) 2004-06-18
AU2003302732A1 (en) 2004-07-09
WO2004047767A3 (en) 2005-04-14
US20090317816A1 (en) 2009-12-24
WO2004047623A3 (en) 2004-10-14
EP1565582A4 (de) 2006-06-07
AU2003302732A8 (en) 2004-07-09
WO2004055196A2 (en) 2004-07-01
US20050214771A1 (en) 2005-09-29
US7510835B2 (en) 2009-03-31
US20050192239A1 (en) 2005-09-01
EP1565579B1 (de) 2009-03-18
EP1565579A2 (de) 2005-08-24
EP1565579A4 (de) 2007-02-14
CA2505784A1 (en) 2004-06-10
WO2004047514A3 (en) 2004-11-04
AU2003298735A1 (en) 2004-06-18
US20050053958A1 (en) 2005-03-10
WO2004047623A2 (en) 2004-06-10
CA2505786C (en) 2011-06-21

Similar Documents

Publication Publication Date Title
DE60326748D1 (de) Verfahren zur identifizierung des brustkrebsrisikos
ATE437962T1 (de) Verfahren für die behandlung von proliferativen erkrankungen von brustzellen
EA200702203A1 (ru) Способы и нуклеиновые кислоты для анализов клеточных пролиферативных нарушений
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2004043232A3 (en) Methods for identifying risk of melanoma and treatments thereof
ATE470723T1 (de) Genexpressionsmarker für die prognose von brustkrebs
WO2005059108A3 (en) Gene expression profiles and methods of use
DE602004015626D1 (de) Bei brustkrebs
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
ATE397098T1 (de) Verfahren zur diagnostik von eierstock endometriose
WO2005027710A3 (en) Methods for identifying subjects at risk of melanoma and treatments thereof
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
ATE456666T1 (de) Verfahren zur auswertung von ribonukleotidsequenzen
WO2004048546A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2006022619A3 (en) Methods for identifying risk of type ii diabetes and treatments thereof
ATE494390T1 (de) Verfahren und nukleinsäuren zur analyse von störungen der proliferation von kolonzellen
ATE449323T1 (de) Zum nachweisen von erkrankungen der brust geeignete reagenzien und verfahren
WO2005118834A3 (en) Methods for identifying risk of breast cancer and treatment thereof
WO2004048548A3 (en) Methods for identifying risk of breast cancer and treatments thereof
NZ584656A (en) Mitochondrial dna deletion between about residues 12317-16254 for use in the detection of cancer
DE60216416D1 (de) Verfahren zum nachweis von chloralhydrat in dichloressigsäure
WO2006063285A3 (en) Methods for identifying risk of breast cancer or prostate cancer and treatments thereof
DE60218995D1 (de) Verfahren zur kit genotypierung von schweinen
EP2112229A3 (de) Verfahren zum Identifizieren des Brustkrebsrisikos und zugehörige Behandlungen
DE60313366D1 (de) Nukleinsäuresonden und Verfahren zum Nachweis einer Zielnukleinsäuresequenz mit zwei oder mehr cis-Nukleinsäurebereichen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties